Tribute Pharmaceuticals Canada Inc (SLRXF) Financial Statements (2023 and Earlier)

Company Profile

Business Address 544 EGERTON ST
LONDON, ON N5W 3Z8
State of Incorp. ON
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,22917,6005,5513,50628,7262,302
Cash and cash equivalents13,22917,6005,5513,50628,7262,302
Receivables7,0285,6003,1242,1451,9231,947
Inventory, net of allowances, customer advances and progress billings3,2362,9221,1941,0378571,059
Inventory3,2362,9221,1941,0378571,059
Prepaid expense299408221180226186
Deferred costs9581,213140128122117
Other current assets19 43 13 
Other undisclosed current assets36457114215370201
Total current assets:25,13328,31410,4157,15031,9375,812
Noncurrent Assets
Property, plant and equipment1,2751,2969791,0121,0261,055
Intangible assets, net (including goodwill)85,91188,05744,06344,55812,97813,221
Goodwill6,8037,5323,5993,5993,5993,599
Intangible assets, net (excluding goodwill)79,10880,52540,46440,9599,3799,622
Deferred costs313326366 287302
Other undisclosed noncurrent assets   359  
Total noncurrent assets:87,49989,67945,40945,92914,29114,578
TOTAL ASSETS:112,632117,99355,82453,08046,22820,390
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:8,2918,7934,2874,3453,3414,057
Other undisclosed accounts payable and accrued liabilities8,2918,7934,2874,3453,3414,057
Debt12,50012,5001,5261,319737583
Derivative instruments and hedges, liabilities4,6459,5755,3593,1083,2517,705
Other liabilities 25   189
Other undisclosed current liabilities16,38219,093    
Total current liabilities:41,81749,98711,1728,7727,32912,535
Noncurrent Liabilities
Long-term debt and lease obligation15,06814,50715,26113,9677,6457,366
Long-term debt, excluding current maturities15,06814,50715,26113,9677,6457,366
Liabilities, other than long-term debt6,9317,594    
Deferred tax liabilities, net6,9317,594    
Total noncurrent liabilities:21,99922,10215,26113,9677,6457,366
Total liabilities:63,81772,08826,43322,73914,97419,901
Stockholders' equity
Stockholders' equity attributable to parent, including:48,81645,90529,39130,34131,254489
Common stock72,44371,09945,02241,18341,18920,159
Additional paid in capital3,9423,7373,0622,7142,6472,504
Accumulated other comprehensive income (loss)19(25)43 13(189)
Accumulated deficit(32,330)(33,909)(25,084)(19,903)(18,943)(21,985)
Warrants and rights outstanding   6,347  
Other undisclosed stockholders' equity attributable to parent4,7425,0036,347 6,347 
Total stockholders' equity:48,81645,90529,39130,34131,254489
TOTAL LIABILITIES AND EQUITY:112,632117,99355,82453,08046,22820,390

Income Statement (P&L) ($ in thousands)

9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
Revenues
(Revenue, Net)
9,0086,4295,5925,4683,8694,041
Cost of revenue
(Cost of Goods and Services Sold)
(1,643)(780)(575)(535)(438)(351)
Other undisclosed gross profit(1,710)(1,546)(1,452)(1,459)(1,550)(1,650)
Gross profit:5,6544,1043,5653,4741,8802,040
Operating expenses(6,411)(5,025)(3,948)(2,615)(2,826)(2,706)
Operating income (loss):(757)(921)(383)858(946)(666)
Nonoperating income (expense)2,846(6,099)(4,129)2344,227(3,195)
Investment income, nonoperating4,883(6,182)(2,696) 4,455(3,206)
Foreign currency transaction gain (loss), before tax(1,084)337(1,433) (228)11
Other nonoperating expense(953)(254)    
Interest and debt expense(798)(595)(596)(573)(304)(298)
Net income (loss):1,290(7,615)(5,108)5202,977(4,159)
Other undisclosed net income (loss) attributable to parent289(1,210)(74)(1,479)  
Net income (loss) attributable to parent:1,579(8,825)(5,181)(960)2,977(4,159)
Other undisclosed net income (loss) available to common stockholders, basic 0  65(242)
Net income (loss) available to common stockholders, diluted:1,579(8,825)(5,181)(960)3,042(4,401)

Comprehensive Income ($ in thousands)

9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
Net income (loss):1,290(7,615)(5,108)5202,977(4,159)
Comprehensive income (loss):1,290(7,615)(5,108)5202,977(4,159)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent308(1,235)(74)(1,479)65(242)
Comprehensive income (loss), net of tax, attributable to parent:1,599(8,850)(5,181)(960)3,042(4,401)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: